As síndromes talassêmicas (?- e ?-talassemia) são as desordens mais comuns e frequentes associadas com eritropoese ineficaz. O desbalanço na produção das cadeias ?- e ?-globinas resulta no comprometimento da produção de eritrócitos, em anemia e aumento de progenitores eritroides no sangue periférico. Enquanto os pacientes homozigóticos afetados por essas desordens demonstram alterações características dos parâmetros relacionados a eritropoese, a relação entre grau de anemia, eritropoese alterada e disfunção do metabolismo de ferro ainda não foram investigados nos indivíduos com ?+-talassemia heterozigótica ou ?+-talassêmia. Duzentos e vinte seis indivíduos (75 do gênero feminino e 151 do gênero masculino) foram recrutados e divididos em 5 grupos: Controle (n=28), doadores de sangue regulares (DSR, n=23), ?+-talassemia heterozigótica (TAT, n=14), ?+-thalassemia (traço ?-talassêmico, TBT, n=20) e ?0-talassemia, (?-talassemia maior, BTM, n=27). As amostras foram analisadas para parâmetros hematológicos (Micros ABX 60); ferro sérico, capacidade total de ligação ao ferro e saturação de transferrina por método colorimétrico (Pointe Scientific, Inc., Canton, MI, USA), ferritina e proteína C-reativa ultra sensível por imunoensaio (Immulite 1000); receptor solúvel de transferrina, eritropoetina, fator de diferenciação do crescimento 15 (R&D Systems) e hepcidina (Intrinsic LifeSciences, La Jolla, CA) por ELISA. As razões sTfR/log ferritina e (hepcidina/ferritina)/sTfR foram calculadas para avaliar o metabolismo do ferro. sTfR/log ferritina pode distinguir depleção dos estoques de ferro de eritropoese deficiente de ferro, enquanto (hepcidina/ferritina)/sTfR pode avaliar os estímulos contrários (disponibilidade de ferro e atividade eritropoética) que controlam a síntese de hepcidina e a absorção de ferro, na ausência de estímulos inflamatórios. Foi demonstrado que TAT teve significativa redução da hepcidina e aumento do receptor solúvel de transferrina, com parâmetros hematológicos relativamente normais. Em contraste, todos os parâmetros hematológicos de TBT foram significativamente diferentes do Controle, incluindo aumento dos níveis do receptor solúvel de transferrina, ferritina, eritropoetina e fator de diferenciação do crescimento 15. Essas alterações em ambos os grupos sugerem um balanço alterado entre eritropoese e metabolismo de ferro. Os índices sTfR/log ferritina e (hepcidina/ferritina)/sTfR estão, respectivamente, aumentado e reduzido comparados ao Controle, proporcional a severidade de cada grupo talassêmico. Em conclusão, destacamos que, pela primeira vez, foram descritas alterações no metabolismo de ferro em indivíduos com ?+-talassemia heterozigótica. Esses dados demonstram que, no contexto da saúde pública, são necessários identificação e acompanhamento dos portadores de ?+-talassemia. / The thalassemia syndromes (?- and ?-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of ?- or ?-globin chain production results in impaired red blood cell synthesis, anemia and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis and dysfunctional iron metabolism have not been investigated in both carriers of ?-thalassemia and ?-thalassemia. 226 subjects (75 females and 151 males) were recruited to this study and divided in 5 groups: Control (n=28), repeat blood donors (DSR, n=23), ?+-thalassemia heterozygous carriers (TAT, n=14), ?+-thalassemia (?-thalassemia trait, TBT, n=20) and ?0-thalassemia, (?-thalassemia major, BTM, n=27). Samples were tested for hematological parameters (Micros ABX 60); serum iron, total iron binding capacity, and transferrin saturation by the colorimetric method (Pointe Scientific, Inc., Canton, MI, USA), ferritin and high sensitive C-reactive protein by immunoassay (Immulite 1000); soluble transferrin receptor, erythropoietin and growth differentiation factor 15 (R&D Systems) and hepcidin (Intrinsic LifeSciences, La Jolla, CA) by ELISA. Were calculated the ratios sTfR/log ferritin and (hepcidin/ferritin)/sTfR to evaluate iron metabolism. sTfR/log ferritin can distinguish storage iron depletion from iron-deficient erythropoiesis, while (hepcidin/ferritin)/sTfR can be utilized to explore and quantify the opposing forces (i.e. iron availability and erythropoietic activity) regulating hepcidin synthesis and iron absorption in absence of inflammatory stimuli. We demonstrate that TAT have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, TBT have all hematological parameters significantly different from controls, including increased soluble transferrin receptor, ferritin, erythropoietin and growth differentiation factor 15 levels. These changings in both groups suggest an altered balance between erythropoiesis and iron metabolism. The indexes sTfR/log ferritin and (hepcidin/ferritin)/sTfR are respectively increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we emphasize that, for the first time in the literature, subjects with heterozygous ?+-thalassemia have altered iron metabolism. Our data demonstrate that within the context of public health, identification and monitoring of patients with ?+-thalassemia are needed.

Die b -Thalassämie gehört weltweit zu den häufigsten monogenen Erbkrankheiten. Die Thalassämien treten endemisch in der Bevölkerung des Mittelmeerraumes, in Westafrika und in weiten Teilen Asiens auf. In der einheimischen Bevölkerung der Bundesrepublik Deutschland gehört die homozygote Form der b -Thalassämie zu den seltenen Erkrankungen. Häufiger ist das Auftreten der heterozygoten Form, die als Differentialdiagnose der mikrozytären, hypochromen Anämie eine besondere Rolle spielt. Blutproben von 214 deutschen Personen mit einer heterozygoten b -Thalassämie wurden mittels Allel-spezifischer Oligonukleotid-Hybridisierung, Restriktionsanalyse und direkter Sequenzierung PCR-amplifizierter DNA analysiert. Insgesamt konnten 96,3 % (206/214) der Proben molekular charakterisiert werden. Die mediterranen Mutationen stellen einen Anteil von etwa 2/3 aller identifizierten Veränderungen, häufig sind insbesondere NS 39, IVS1-110 G ® A und IVS1-1 G ® A. Das übrige Mutationsspektrum setzt sich aus sehr seltenen Mutationen (IVS1-1 G ® T, IVS1-2 T ® G, IVS1-2 T ® C, NS 15 G ® A, NS 121 G ® T, FS 8/9 +G, FS 44 -C, FS 51 -C, FS 82/83 -G, Initiations-Kodon-Mutationen ATG ® ACG/ ® GTG/ ® ATA) und einer neuen Mutation (IVS1-129 A ® G) zusammen. In 6 Fällen konnte nach vollständiger molekularer Analyse kein Gendefekt als Ursache der b -Thalassämie gefunden werden. Diese Probanden könnten b -Thalassämiedeterminanten tragen, die nicht an den b -Globingen-Komplex gekoppelt sind oder regulative Sequenzen außerhalb des b -Globingens darstellen. Die erhobenen Daten zeigen, daß der Ursprung der b -Thalassämie in der deutschen Bevölkerung in den Mittelmeerländern liegt, ein Drittel der Fälle scheint sich jedoch lokal entwickelt zu haben. / The b -thalassemia belongs to the most common monogenic disorders worldwide. Endemically in the Mediterranean population, some parts of Asia and Western Africa, b -thalassemia is a rare disease in Germany. Nevertheless, heterozygous forms of b -thalassemia minor occur more frequently in the German population and should be considered in the differential diagnosis of hypochromic anemia. To investigate the molecular biological background of b -thalassemia in Germany, 214 non-immigrant German individuals suffering from heterozygous b -thalassemia were characterized by allele-specific oligonucleotid hybridization, restriction analysis and sequencing of the b -globin gene. By these techniques, 26 different mutations were identified. Most frequently, the Mediterranean mutations NS 39, IVS1-110 G ® A, and IVS1-1 G ® A were detected. Although otherwise rare, the frameshift mutation of codon 83 (FS 83 -G) was also relatively common (5 %) in the analyzed population. Other previously described mutations (IVS1-1 G ® T, IVS1-2 T ® G, IVS1-2 T ® C, NS 15 G ® A, NS 121 G ® T, FS 8/9 +G, FS 44 -C, FS 51 -C, initiation codon mutation ATG ® ACG/ ® GTG/ ® ATA) were demonstrated in < 10 individuals. Interestingly, sequence analysis identified a novel mutation affecting position -2 of the splice acceptor site (IVS1-129 A ® G). In 6 individuals diagnosed as heterozygous b -thalassemia, a mutation of the b -globin gene could not be demonstrated. The data indicate the b -thalassemia to be introduced from the Mediterranean population into Germans in two-thirds of the cases whereas the remaining third probably is of local origin.

L’érythropoïèse est le processus de formation des globules rouges. L’anémie demeure à l’heure actuelle un problème de santé publique majeur. Par conséquent, une meilleure compréhension des mécanismes impliqués dans le contrôle de ce processus dans des conditions physiologiques et pathologiques, ainsi que l’établissement de stratégies thérapeutiques ciblées constituent un enjeu de recherche majeur. Le récepteur de la transferrine 1 (CD71/RTf1) est un élément essentiel de l'érythropoïèse, la majorité des travaux de recherche étant focalisés sur son rôle indéniable dans le métabolisme du fer. Cependant, de nouveaux ligands du RTf1 ont été découverts ouvrant de nouvelles perspectives relatives aux fonctionnalités de ce récepteur. Ayant démontré que le RTf1 fixait les immunoglobulines A1 (IgA1), nous nous sommes intéressés au rôle des IgA1 dans l’érythropoïèse. Nous montrons que le RTf1 lié aux polymères d'IgA1 (pIgA1) induit la croissance et une augmentation de la prolifération des érythroblastes en concentration sous-optimale d'érythropoïétine (Epo). De même, l'expression transgénique d’IgA1 humaine (souris alpha1-KI), ou le traitement de souris de type sauvage avec les pIgA1 permettent une récupération accélérée de l’anémie aiguë. L’engagement du RTf1 module la sensibilité à l'Epo, en diminuant le seuil d'activation cellulaire, et en induisant les voies de signalisation MAPK/ERK et phosphatidylinositol-3-kinase (PI3K/AKT). Ces données mettent en évidence un nouveau rôle du RTf1 en tant que régulateur positif de l'érythropoïèse. Parallèlement au RTf1, nous avons identifié un autre récepteur pouvant constituer une cible thérapeutique pour corriger une érythropoïèse inefficace : le récepteur de l’activine de type IIA (ActRIIA). Dans un modèle murin de Beta-thalassémie intermédiaire (Hbbth1/th1), résultant d'une déficience génétique de la chaîne Beta de la globine, nous montrons que l'administration d'une protéine de fusion constituée du domaine extracellulaire de l’ActRIIA lié à un fragment Fc d’IgG de souris (RAP-011), corrige l'anémie, augmente le taux d'hémoglobine et diminue la splénomégalie. Ce traitement favorise l’érythropoïèse splénique et diminue la saturation de la transferrine et l’hémolyse. Fait intéressant, des niveaux élevés de GDF11 (Growth Differentiation Factor 11) sont observés sur des coupes spléniques de souris thalassémiques ainsi que dans le sérum de patients thalassémiques. In vivo, l’inhibition de l’interaction GDF11/ActRIIa par le RAP-011 favorise l’apoptose des érythroblastes précoces par la voie Fas/FasLigand. Ces résultats suggèrent que l’activation constitutive des signaux GDF11/ActRIIA contribue à l’établissement d’une érythropoïèse inefficace caractéristique de la Beta-thalassémie. La neutralisation de cette signalisation inverse ce processus. En conclusion, nos travaux ouvrent de nouvelles perspectives dans la compréhension de l'hématopoïèse normale et pathologique, et pourraient conduire à envisager des traitements innovants pour l'anémie. / Anemia produced by a variety of underlying causes is the most common disorder of the blood, and remains a major global public health problem associated with a poor quality of life for many patients. Thus, better understanding the erythroid process in physiological and pathological conditions, and developing new strategies to boost erythropoiesis appear of great interest. Transferrin receptor 1 (CD71/TfR1) plays an essential role in erythropoiesis, and investigations of TfR1 functions have been focused on their undeniable role in iron metabolism. However, recent data demonstrate that TfR1 is a multi-ligand receptor that participates in a wide array of cellular functions. We have identified TfR1 as a receptor for A1 isotype immunoglobulins (IgA1). In this work, we show that pIgA1s are able through their interaction with the TfR1, to stimulate erythropoiesis by sensitizing erythroblasts to Epo. Likewise, transgenic expression of human IgA1 (Alpha1-KI mice) or treatment of wild-type mice with pIgA1 accelerated recovery from acute anemia. TfR1 engagement by pIgA1 increased cell sensitivity to Epo by inducing activation of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling pathways. These findings unveiled a new role of TfR1 as a signaling competent molecule positively regulating erythropoiesis. In addition to TfR1, our work identifies another receptor as a putative target for correcting ineffective erythropoiesis: the activin receptor IIA (ActRIIA). Indeed, using a mouse model of Beta-thalassemia intermedia (Hbbth1/th1) resulting from a genetic deficiency of Beta-globin chain, we show that administration of a ligand trap (named RAP-011), consisting in a fusion protein between the extracellular domain of ActRIIA and the Fc fragment of a mouse IgG, improves anemia, increases total hemoglobin levels and decreases splenomegaly. In addition, targeting ActRIIa signaling corrects ineffective erythropoiesis in the spleen, reduces hemolysis and transferrin saturation. Interestingly, high levels of Growth Differentiation Factor 11 (GDF11) are detected in spleen sections from Beta-thalassemic mice, as well as in sera from thalassemic patients. In addition, the inactivation of GDF11 promotes terminal erythroblast differentiation. Finally, blockade of the GDF11/ActRIIa signaling, promotes premature apoptosis of early erythroblasts through induction of Fas/FasLigand pathway. Therefore, these results first suggest that constitutive GDF11/ActRIIa signaling pathway may promote ineffective erythropoiesis in Beta-thalassemia intermedia, and secondly, support the use of ActRIIa traps for the treatment of chronic anemia and ineffective erythropoiesis. Altogether, these results open new perspectives in the understanding of normal and pathological hematopoiesis and lead to propose innovative treatments for anemia.

Resumo: A beta talassemia é um dos mais freqüentes distúrbios genéticos no mundo. Estima-se que 1,5% a 3% da população mundial seja portadora do traço talassêmico. Esses portadores geralmente são oligo ou assintomáticos e têm uma expectativa de vida semelhante à dos não portadores. Entretanto, níveis elevados de ferritina sérica têm sido observados em alguns estudos comparativos entre beta talassemia heterozigota e não portadores e, alguns indivíduos, que nunca foram transfundidos, apresentam sinais clínicos e laboratoriais de sobrecarga de ferro. A fisiopatologia dessa complicação continua em discussão. Vários pesquisadores têm sugerido um efeito modulador da mutação do gene da beta globina e mutações em genes codificadores de proteínas relacionadas ao metabolismo do ferro. Mutações no gene HFE são as mais freqüentemente associadas à hemocromatose hereditária. O objetivo do presente trabalho foi avaliar a freqüência das mutações C282Y e H63D no gene HFE em portadores de beta talassemia heterozigota e analisar sua influência no metabolismo do ferro. Foram estudados 162 portadores de beta talassemia heterozigota, residentes na cidade de São Carlos ou região, caucasóides e, acompanhados no serviço de Hematologia. O diagnóstico de traço talassêmico foi confirmado em todos por meio do eritrograma e da quantificação da Hb A2 e Hb fetal por HPLC. O metabolismo do ferro foi avaliado pelas dosagens de ferro sérico, capacidade total de ligação do ferro, ferritina e saturação da transferrina e, a análise molecular das mutações no gene HFE, pela técnica de PCR-RLFP. Foram realizadas análises de correlação linear de Pearson por idade e gênero entre hemoglobina... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Beta thalassemia is one of the most frequent genetic disorder in the world. It is estimated that 1.5% to 3% of the world population is a thalassemia carrier. These individuals are generally slightly symptomatic or asymptomatic and they have a life expectancy similar to those who are non-carriers. However, high levels of serum ferritin have been observed in some comparative studies between heterozygous for beta thalassemia and non-carriers, and some individuals that were never transfused, present clinic and laboratories signs of iron overload. The physiopathology of this disease continues in discussion. Several researchers have suggested a modulator effect from the mutation of the beta globin gene and mutations in genes related with the iron metabolism. Mutations of the gene HFE are the most frequently associated to the hereditary hemochromatosis. The aim of this study was evaluate the frequency of C282Y and H63D mutations in the HFE gene in beta thalassemia carriers, and analyze its influence in the iron metabolism. 162 beta thalassemia carriers, Caucasoid, residing in the city of Sao Carlos or region and accompanied in the Hematology service were studied. The diagnostic of thalassemia trait was confirmed in every one through a complete erythrogram and quantification of Hb A2 and Hb fetal by HPLC. The iron metabolism was evaluated by serum iron, total iron-binding capacity, serum ferritin and percent saturation of transferring. The molecular analysis of the mutations in the HFE gene was made by PCR-RLFP. There were made analysis of linear Pearson' correlation, by age and gender, among hemoglobin, Hb A2, VCM and among reticulocytes count and the values of saturation of transferrin and serum ferritin. / Orientador: Claudia Regina Bonini Domingos / Coorientador: Antonio José Manzato / Banca: Celso Carlos de Campos Guerra / Banca: Paula Rahal Liberatore / Mestre

Le premier objectif de cette thèse était de déterminer les effets isolés et combinés de l'alpha thalassémie, des polymorphismes inducteurs (QTLs) de l'HbF et du génotype G6PD dans un contexte d'évolution naturelle de la drépanocytose (Etudes 1 et 2). L'étude 1 a permis d'évaluer pour la première fois les fréquences alléliques de ces gènes modificateurs chez 301 enfants sénégalais SS. Contrairement aux autres populations africaines, le Variant Betica de la G6PD était majoritaire par rapport au variant A(-). De plus, 12% de notre cohorte avait un déficit en G6PD combiné à une absence d'alpha-thalassémie. Ces patients-là seront à privilégier pour la réalisation d'un Doppler transcrânien. Les résultats obtenus dans l'étude 2 nous ont permis de conclure que l'alpha-thalassémie et les QTLs de l'HbF sont interdépendants et ne doivent pas être étudiés séparément pour une prédiction clinique précise. En effet, une combinaison d'alpha-thalassémie avec au moins 2 QTLs de l'HbF est nécessaire pour retarder de manière significative la première complication de la maladie. Cependant, une alpha-thalassémie homozygote, même associée à 3 à 6 QTLs de l'HbF, augmente la fréquence des CVO pendant l'enfance. Par conséquent, une alpha-thalassémie hétérozygote avec au moins deux QTL HbF constituerait le génotype le plus favorable relativement à la survenue des CVO. Le deuxième objectif de cette thèse était d'étudier les interrelations entre le stress oxydant (phénotype et génotype) et la sévérité clinique de la maladie (Etudes 3 à 4). La drépanocytose est caractérisée par un stress oxydatif élevé pouvant expliquer une partie des manifestations cliniques. Nos résultats ont montré que l'alpha-thalassémie homozygote semble diminuer le stress oxydatif, ce qui contribuerait à son effet protecteur sur certaines complications du sous-phénotype hémolytique. En outre, les patients qui ont le moins d'hospitalisations et de CVO semblent présenter une meilleure défense antioxydante (activités catalase et GPx augmentées). Dans l'étude 4 nous avons étudié 4 SNPs de gènes du stress oxydant (rs4880 du gène SOD2, rs207454 du gène XO, rs233322 du gène MPO et rs35652124 du gène NFE2L2). Le SNP rs4880 aurait un effet favorable au niveau biologique (réticulocytose moindre, activité GPx augmentée) mais sans traduction clinique associée. Il en est de même pour rs233322 qui serait associé à une hémolyse et à un stress oxydatif (AOPP) plus importants. En revanche, une tendance à un effet protecteur de rs207454 vis-à-vis de certaines complications (hospitalisations, ostéonécrose, sepsis, STA) a été observée. Notre travail contribue à la compréhension de l'impact des gènes modificateurs dans la drépanocytose. Il pourrait donc permettre, via une sélection positive des patients à risque, d'améliorer la prise en charge de la maladie dans les pays où les traitements de fond (hydroxyurée, doppler transcrânien, échanges transfusionnels) ne peuvent être proposés à tous / The primary objective of this thesis was to determine the isolated and combined effects of alpha-thalassemia, inductors polymorphisms (QTLs) of HbF and genotype G6PD in a context of natural progression of sickle cell disease (Studies 1 and 2). Study 1 was undertaken to evaluate for the first time the allelic frequencies of these modifiers genes in 301 Senegalese SS children. Unlike other African populations, the G6PD Betica Variant was predominant over the A (-) variant. In addition, 12% of our cohort had G6PD deficiency combined with no alpha-thalassemia. These patients will be favoured for the realization of a transcranial doppler. The results obtained in Study 2 allowed us to conclude that alpha thalassemia and QTLs of HbF are interdependent and should not be studied separately for accurate clinical prediction. Indeed, a combination of alpha thalassemia with at least 2 QTLs of HbF is required to significantly delay the first complication of the disease. However, a homozygous alpha thalassemia, even associated with 3 to 6 QTLs of HbF, increases the frequency of CVOs during childhood. Therefore, a heterozygous alpha-thalassemia with at least two QTL HbFs would be the most favourable genotype for the occurrence of CVOs. The second objective of this thesis was to study the interrelationships between oxidative stress and the clinical severity of the disease (Studies 3 to 4). Sickle cell disease is characterized by high oxidative stress that may explain some of the clinical manifestations. Our results showed that homozygous alpha-thalassemia appears to reduce oxidative stress, which would contribute to its protective effect on certain complications of the hemolytic sub-phenotype. In addition, patients with the least hospitalization and CVO appear to have better antioxidant defense (catalase and GPx activities increased). In Study 4 we studied 4 SNPs of oxidative stress genes (rs4880 of the SOD2 gene, rs207454 of the XO gene, rs233322 of the MPO gene and rs35652124 of the NFE2L2 gene). The rs4880 SNP would have a favourable effect on the biological level (less reticulocytosis, increased GPx activity) but without associated clinical translation. The same is true for rs233322, which is associated with greater haemolysis and oxidative stress (AOPP). On the other hand, a tendency to a protective effect of rs207454 for some complications (hospitalizations, osteonecrosis, sepsis, STA) was observed. Our work contributes to the understanding of the impact of modifiers genes in sickle cell disease. It could therefore, through a positive selection of at-risk patients, improve the management of the disease in countries where the basic treatments (hydroxyurea, transcranial doppler, blood transfusion) cannot be offered to all

Orientadores: Maria de Fatima Sonati, Maricilda Palandi de Mello / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-10T14:17:59Z (GMT). No. of bitstreams: 1 Wenning_MarciaReginadeSouzaCossa_D.pdf: 2460425 bytes, checksum: bd59f41846de3b0439b17450b12154a1 (MD5) Previous issue date: 2007 / Resumo: A Doença da Hb H resulta da remoção ou inativação de três dos quatro genes da cadeia a da hemoglobina normalmente presentes no genoma diplóide e é caracterizada por anemia hemolítica crônica de intensidade moderada a grave. Os pacientes apresentam microcitose, hipocromia e poiquilocitose, com cerca de 25 a 30% de Hb Bart¿s (?4) ao nascimento e 5-30% de Hb H (ß4) na vida adulta. Embora a base molecular da doença tenha influência nos níveis de Hb H produzidos, uma heterogeneidade em relação a esse aspecto tem sido observada mesmo em pacientes com genótipos a idênticos, sugerindo que outros fatores contribuem para esta diversidade além dos determinantes talassêmicos. No presente trabalho, procuramos identificar transcritos diferencialmente expressos nos reticulócitos de dois pacientes com Doença da Hb H, irmãos, de origem étnica mista (chinesa e africana), um do sexo masculino, 21 anos de idade, com 18% de Hb H (MKS), e outro do sexo feminino, 19 anos, com 5% desta Hb (FKS), ambos com genótipo -a3.7/--SEA. O método envolveu a técnica de Differential Display Reverse Transcription-Polymerase Chain Reaction (DDRT-PCR) e a realização de Hibridização Subtrativa Supressiva (SSH). A validação dos achados foi feita pela Reação em Cadeia da Polimerase quantitativa em Tempo Real (qRT-PCR). Quatro perfis diferenciais de expressão foram selecionados, todos mais representados no paciente com maior nível de Hb H. Dois foram detectados por ambas as abordagens metodológicas: um transcrito altamente homólogo à parte do gene da PIP5KIIA (fosfatidilinositol 4-fosfato-5 quinase tipo II a) e outro ao gene da cadeia ß da hemoglobina humana. Os outros dois transcritos, selecionados apenas pela SSH, apresentararam similaridade ao gene FAM46C (Family with sequence similarity 46, member C), que corresponde a uma proteína hipotética de função indeterminada, e ao gene EIF4E-BP1 (eukariotic translation initiation factor 4E ¿ binding protein 1), que codifica uma proteína regulatória da tradução com capacidade de inibição do fator eIF4E (eukariotic translation initiation factor 4E). Na tentativa de identificar os mecanismos responsáveis pelo aumento dos transcritos da PIP5KIIA e da globina ß nos reticulócitos de MKSalguns outros genes, relacionados às vias de atuação ou ao processo de transcrição dos primeiros, tiveram sua expressão também avaliada pela qRT-PCR. Os resultados obtidos, embora não conclusivos, sugeriram que a diferença nos níveis de Hb H apresentada pelos pacientes aqui estudados está correlacionada com a taxa de síntese de cadeias ß, e que a enzima PIP5KIIA, provavelmente via sinalização celular pelo fosfatidilinositol, de alguma maneira participa de sua regulação. O significado destes achados e o papel dos transcritos dos genes FAM46C e EIF4E-BP1 devem ser futuramente investigados para uma melhor compreensão dos mecanismos de regulação da expressão dos genes da globina ß em pacientes com talassemia a / Abstract: Hb H disease results from the inactivation of three of the four a-globin genes normally present on diploid genome and it is characterized by a moderate to severe chronic hemolytic anemia. Patients usually present microcytosis, hypochromia and poikilocytosis, with 25 to 30% of Hb Bart¿s (?4) at birth and 5 to 30% of Hb H (ß4) in adult life. Although the molecular base of this disease influences the Hb H levels produced, some heterogeneity has been observed in relation to this aspect, even in patients with identical a genotypes, thus suggesting that other factors contribute to this diversity besides a-thalassemic determinants. The aim of the present study was to identify differentially expressed transcripts in the reticulocytes from two patients with Hb H disease, siblings, from Chinese and African origins, a 21-year- old male (MKS) with 18% of Hb H and a 19-year-old female (FKS) with 5% of Hb H, both with genotype -a3.7/--SEA. The methodology involved two techniques: the Differential Display Reverse Transcription-Polymerase Chain Reaction (DDRT-PCR) and the Suppression Subtractive Hybridization (SSH). Quantitative real time PCR (qRT-PCR) experiments were used to confirm some results. Four differentially expressed profiles were obtained, all of them better represented in the subject with the highest Hb H level. Two transcripts were detected by both methodological approaches, one being highly similar to PIP5KIIA gene (Phosphatidylinositol ¿ 4 phosphate 5-kinase, type II a) and the other one similar to human ß-globin gene. Two others transcripts were selected only by SSH and they showed to be to FAM 46C (Family with sequence similarity 46, member C) and EIF4E-BP1 (eukariotic translation initiation factor 4E-binding protein 1) gene homologues. In order to identify the mechanisms that are responsible for the transcripts PIP5KIIA and ß- globin increase in the reticulocytes from MKS patient, some other genes related to the transcriptional process also had its expression evaluated by qRT-PCR. Although not conclusive, our results suggest that the difference between the Hb H levels, showed by the subjects here studied, is correlated with ß-globin synthesis rate and that PIP5KIIA may participate of its regulation, probably by cell signalizing through Phosphatidylinositol. Studies, particularly involving a higher number of patients, and experiments aimed at elucidating the PIP5KIIA function in erythroid cells, should help to understand this process. The initiation factor -4E binding protein (EIF4E-BP1) and its capacity to bind to eIF4E, acts as negative regulator of cell growth. Its overexpression was detected in the patient with the highest HbH level. The significance of these findings and the role of the FAM46C and EIF4E-BP1 gene transcripts should be further investigated so that the regulating of the ß-globin gene expression in a-thalassemic patients can be better understood / Doutorado / Medicina Experimental / Doutor em Fisiopatologia Medica

Made available in DSpace on 2014-07-29T15:10:32Z (GMT). No. of bitstreams: 1 tese final Karlla.pdf: 1794329 bytes, checksum: 2a2d0436bd4d9a7eeebe61077580e8f9 (MD5) Previous issue date: 2009-03-27 / Alpha thalassemia is a syndrome resulting from disturbances in the synthesis of alpha globin chain that forms the tetramer of the hemoglobin molecule. Alpha thalassemia is classified into four types according to the number of alpha genes affected: silent carrier (-&#945;/&#945;&#945;), alpha thalassemia trait (--/&#945;&#945; or -&#945;/-&#945;) Hemoglobin H disease (-- /-&#945;), and fetalis hydrops (--/--). The decrease in synthesis of alpha globin causes inadequate production of hemoglobin resulting in hypochromic and microcytic anaemia. Also it causes accumulation of beta chains, inside the erythrocytes, resulting in formation of beta chain tetramer of hemoglobin called Hb H. Clinically the individual with thalassemia can be asymptomatic or present severe anemia. Asymptomatic forms of thalassemia, silent carrier and alpha thalassemia trait, are more difficult to diagnose because of the inclusions bodies of Hb H are not always present. In these situations it is necessary to research the molecular characterization of the genotype and confirming the presence of alpha thalassemia. This is mainly because the diagnosis by conventional methods, although important, is limited and imprecise. This study evaluated some of the traditional laboratory methods in the detection of alpha thalassemia and associated molecular characterization of the more prevalent deletion forms &#945;3,7 and &#945;4,2. For confirmation and characterization of alpha thalassemia, new oligonucleotides were designed. By conventional PCR technique, using 3.7F/KGB01 primers it was possible to detect the deletion &#945;3,7, differentiating the normal genotype (&#945;&#945;/&#945;&#945;), the heterozygote (-&#945;3,7/&#945;&#945;), and homozygous (-- &#945;3,7/- &#945;3,7). Although it was designed to detect the deletion &#945;3,7, this primers also identified the deletion &#945;4,2 when in homozigose (-&#945;4,2/- &#945;4,2). The primers KGB04/KGB05 detected the deletion &#945;4,2, but without differentiating between the heterozygous and homozygous genotype. The most prevalent deletion founded was the &#945;4,2 (20.0%) which represents 9.2% in the homozygous form (- &#945;4,2/-&#945;4,2). The deletion &#945;3,7 in the heterozygous form was detected in 12.3% of patients. The data demonstrate that the importance of molecular detection for alpha thalassemia is not limited only to the definition of the genotype, but also confirmation of the presence in patients with abnormal erythrogram values, with regular erythrogram values, with values closed to the boundary values and in neonates. / A talassemia alfa é uma síndrome resultante de distúrbios na síntese da cadeia da globina alfa que formam o tetrâmero da molécula da hemoglobina. A talassemia alfa é classificada em quatro tipos de acordo com o número de genes alfa afetado: portador silencioso (-&#945;/&#945;&#945;); traço alfa talassêmico (--/&#945;&#945; ou - &#945;/-&#945;); doença de hemoglobina H (--/-&#945;) e hidropsia fetal (--/--). A diminuição na síntese de globina alfa causa a produção inadequada de hemoglobina que resulta em anemia microcítica e hipocrômica. Causa também o acúmulo de cadeias do tipo beta, no interior do eritrócito, pela falta de balanceamento com a síntese da globina alfa afetada. O resultado deste desbalanceamento é a formação de tetrâmeros de cadeias beta denominados Hb H. Clinicamente o indivíduo portador de talassemia alfa pode ser assintomático ou apresentar anemia severa. As formas assintomáticas da talassemia alfa, o portador silencioso e o traço alfa talassêmico, são mais difíceis de diagnosticar, pois os corpúsculos de Hb H nem sempre estão presentes. Para estas situações faz-se necessária a investigação molecular visando a caracterização do genótipo e a confirmação da presença da talassemia alfa. Este fato se deve principalmente porque o diagnóstico através de métodos clássicos não moleculares, apesar de importantes, é limitado e impreciso. O presente trabalho avaliou alguns dos métodos laboratoriais clássicos na detecção de talassemia alfa e associou a caracterização molecular das formas delecionais mais prevalentes &#945;3,7 e &#945;4,2. Para a confirmação e caracterização da talassemia alfa, foram desenhados novos oligonucleotídeos. Através da técnica convencional da PCR, utilizando o par de oligonucleotídeos 3.7F/KGB01 foi possível detectar a deleção &#945;3,7, diferenciando o genótipo normal (&#945;&#945;/&#945;&#945;), do heterozigoto ( &#945;3,7/&#945;&#945;) e do homozigoto ( &#945;3,7/ &#945;3,7). Apesar de ter sido desenhado para detectar a deleção &#945;3,7, este par também permitiu detectar a deleção &#945;4,2 quando em homozigose ( &#945;4,2/ &#945;4,2). Utilizando o par KGB04/KGB05 foi possível detectar a deleção &#945;4,2, porém sem diferenciar entre o genótipo heterozigoto e homozigoto. A deleção mais prevalente encontrada foi a &#945;4,2 (20,0%) sendo que destas podemos afirmar que 9,2% estão na forma homozigótica ( &#945;4,2/ &#945;4,2). A deleção do tipo &#945;3,7 na forma heterozigótica foi detectada em 12,3% dos pacientes. Os dados obtidos revelam que a importância da detecção molecular para talassemia alfa não se restringe apenas na definição do genótipo, mas também na detecção deste tipo de talassemia em pacientes que apresentam: quadros hematológicos alterados, quadros hematológicos normais, mas com valores próximos aos valores limítrofes e em neonatos.

As síndromes talassêmicas (?- e ?-talassemia) são as desordens mais comuns e frequentes associadas com eritropoese ineficaz. O desbalanço na produção das cadeias ?- e ?-globinas resulta no comprometimento da produção de eritrócitos, em anemia e aumento de progenitores eritroides no sangue periférico. Enquanto os pacientes homozigóticos afetados por essas desordens demonstram alterações características dos parâmetros relacionados a eritropoese, a relação entre grau de anemia, eritropoese alterada e disfunção do metabolismo de ferro ainda não foram investigados nos indivíduos com ?+-talassemia heterozigótica ou ?+-talassêmia. Duzentos e vinte seis indivíduos (75 do gênero feminino e 151 do gênero masculino) foram recrutados e divididos em 5 grupos: Controle (n=28), doadores de sangue regulares (DSR, n=23), ?+-talassemia heterozigótica (TAT, n=14), ?+-thalassemia (traço ?-talassêmico, TBT, n=20) e ?0-talassemia, (?-talassemia maior, BTM, n=27). As amostras foram analisadas para parâmetros hematológicos (Micros ABX 60); ferro sérico, capacidade total de ligação ao ferro e saturação de transferrina por método colorimétrico (Pointe Scientific, Inc., Canton, MI, USA), ferritina e proteína C-reativa ultra sensível por imunoensaio (Immulite 1000); receptor solúvel de transferrina, eritropoetina, fator de diferenciação do crescimento 15 (R&D Systems) e hepcidina (Intrinsic LifeSciences, La Jolla, CA) por ELISA. As razões sTfR/log ferritina e (hepcidina/ferritina)/sTfR foram calculadas para avaliar o metabolismo do ferro. sTfR/log ferritina pode distinguir depleção dos estoques de ferro de eritropoese deficiente de ferro, enquanto (hepcidina/ferritina)/sTfR pode avaliar os estímulos contrários (disponibilidade de ferro e atividade eritropoética) que controlam a síntese de hepcidina e a absorção de ferro, na ausência de estímulos inflamatórios. Foi demonstrado que TAT teve significativa redução da hepcidina e aumento do receptor solúvel de transferrina, com parâmetros hematológicos relativamente normais. Em contraste, todos os parâmetros hematológicos de TBT foram significativamente diferentes do Controle, incluindo aumento dos níveis do receptor solúvel de transferrina, ferritina, eritropoetina e fator de diferenciação do crescimento 15. Essas alterações em ambos os grupos sugerem um balanço alterado entre eritropoese e metabolismo de ferro. Os índices sTfR/log ferritina e (hepcidina/ferritina)/sTfR estão, respectivamente, aumentado e reduzido comparados ao Controle, proporcional a severidade de cada grupo talassêmico. Em conclusão, destacamos que, pela primeira vez, foram descritas alterações no metabolismo de ferro em indivíduos com ?+-talassemia heterozigótica. Esses dados demonstram que, no contexto da saúde pública, são necessários identificação e acompanhamento dos portadores de ?+-talassemia. / The thalassemia syndromes (?- and ?-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of ?- or ?-globin chain production results in impaired red blood cell synthesis, anemia and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis and dysfunctional iron metabolism have not been investigated in both carriers of ?-thalassemia and ?-thalassemia. 226 subjects (75 females and 151 males) were recruited to this study and divided in 5 groups: Control (n=28), repeat blood donors (DSR, n=23), ?+-thalassemia heterozygous carriers (TAT, n=14), ?+-thalassemia (?-thalassemia trait, TBT, n=20) and ?0-thalassemia, (?-thalassemia major, BTM, n=27). Samples were tested for hematological parameters (Micros ABX 60); serum iron, total iron binding capacity, and transferrin saturation by the colorimetric method (Pointe Scientific, Inc., Canton, MI, USA), ferritin and high sensitive C-reactive protein by immunoassay (Immulite 1000); soluble transferrin receptor, erythropoietin and growth differentiation factor 15 (R&D Systems) and hepcidin (Intrinsic LifeSciences, La Jolla, CA) by ELISA. Were calculated the ratios sTfR/log ferritin and (hepcidin/ferritin)/sTfR to evaluate iron metabolism. sTfR/log ferritin can distinguish storage iron depletion from iron-deficient erythropoiesis, while (hepcidin/ferritin)/sTfR can be utilized to explore and quantify the opposing forces (i.e. iron availability and erythropoietic activity) regulating hepcidin synthesis and iron absorption in absence of inflammatory stimuli. We demonstrate that TAT have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, TBT have all hematological parameters significantly different from controls, including increased soluble transferrin receptor, ferritin, erythropoietin and growth differentiation factor 15 levels. These changings in both groups suggest an altered balance between erythropoiesis and iron metabolism. The indexes sTfR/log ferritin and (hepcidin/ferritin)/sTfR are respectively increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we emphasize that, for the first time in the literature, subjects with heterozygous ?+-thalassemia have altered iron metabolism. Our data demonstrate that within the context of public health, identification and monitoring of patients with ?+-thalassemia are needed.

Text in English / This research explores the meaning of the first and second-order therapeutic stances with reference to the therapist's professional and personal development. The dominant positivist paradigm was reflected in the therapist's initial position of expert observer, outside of the observed. The observed phenomena were a group of children suffering from thalassemia major, a terminal genetic disease, and their mothers. The initial idea of short-term intervention and focus on the observed evolved into six-year journey where the observer and the observed became an interconnected unit of observation, understanding and change. A first-order stance led to therapeutic stuckness, where the therapist's confrontation with her therapeutic failure and the limitations of the dominant paradigm provoked a deconstruction of the expert position and promoted a self-reflexive therapeutic stance. The author's self-searching process took her back to her personal self, her family of origin and the ''wounded healer". The researcher moved from an initial disconnection between her professional and personal selves to an awareness of the interface between the two and, ultimately, to a unification of her professional and personal selves. Such development involved an individuation process moving from a narcissistic belief in her objective stance towards a therapeutic stance where she sees herself less as a powerful agent of change and moves to an increasingly higher order of integration of the professional and personal selves (Skovholt & Ronnestad, 1992). The process with the children and mothers shifted from a focus on compliance and medical issues to more personal and emotional stories. The therapist's participation and collaborative stance created a context for change, where greatly improved medical compliance was just one of the many transformations experienced by all the participants. The researcher speculates that development of a second-order stance requires second-order change, which comes "at the end of long, often frustrating mental and emotional labor" (Watzlawick et al., 1974, p. 23), promoting integration between the professional and personal selves of the therapist. The researcher therefore contends that this process has important implications for psychotherapy training, supervision and continuing education. / Psychology / D. Litt. et Phil. (Psychology)

Text in English / This research explores the meaning of the first and second-order therapeutic stances with reference to the therapist's professional and personal development. The dominant positivist paradigm was reflected in the therapist's initial position of expert observer, outside of the observed. The observed phenomena were a group of children suffering from thalassemia major, a terminal genetic disease, and their mothers. The initial idea of short-term intervention and focus on the observed evolved into six-year journey where the observer and the observed became an interconnected unit of observation, understanding and change. A first-order stance led to therapeutic stuckness, where the therapist's confrontation with her therapeutic failure and the limitations of the dominant paradigm provoked a deconstruction of the expert position and promoted a self-reflexive therapeutic stance. The author's self-searching process took her back to her personal self, her family of origin and the ''wounded healer". The researcher moved from an initial disconnection between her professional and personal selves to an awareness of the interface between the two and, ultimately, to a unification of her professional and personal selves. Such development involved an individuation process moving from a narcissistic belief in her objective stance towards a therapeutic stance where she sees herself less as a powerful agent of change and moves to an increasingly higher order of integration of the professional and personal selves (Skovholt & Ronnestad, 1992). The process with the children and mothers shifted from a focus on compliance and medical issues to more personal and emotional stories. The therapist's participation and collaborative stance created a context for change, where greatly improved medical compliance was just one of the many transformations experienced by all the participants. The researcher speculates that development of a second-order stance requires second-order change, which comes "at the end of long, often frustrating mental and emotional labor" (Watzlawick et al., 1974, p. 23), promoting integration between the professional and personal selves of the therapist. The researcher therefore contends that this process has important implications for psychotherapy training, supervision and continuing education. / Psychology / D. Litt. et Phil. (Psychology)